Health & Wellness
Viit Health
Non-Invasive Glucose & Biomarker Monitor for Wellness
Mesa,
AZ
Investment type:
Equity
(SAFE)
Target raise:
$618,000
- $618,000
Minimum investment:
$100
$100
End date:
Nov 05, 2023
Nov 05, 2023
ended
Share
Highlights
- 13 Clinical Trials, 93% accuracy for regular blood glucose levels, 150 units already requested
- +$2.5M raised from leading private investors. $3M granted for R&D to background dev company.
- Twice Grant Awardee by the Mexican National Council of Science and Technology
- Massive Wellness market potential of $1.5 T and $966 B diabetes-related global health expenditure
Our Story
Viit Health develops computer vision technology for wellness monitoring. We create integral consumer healthcare solutions comprised of electronic devices, image processing engines and user friendly software applications, which are used together to accurately and non-invasively identify different biomarkers (blood glucose levels, oxygenation, heart rate and temperature) and derive meaningful personalized wellness insights from such data. Our hardware uses advanced optical techniques such as Near Infrared Transmittance Spectroscopy (NIR) and Photoplethysmography (PPG) to identify the spectral footprint of particular biochemical compounds in human tissue and volumetric variations of the blood. Such data is then analyzed by intelligent image processing algorithms that have been trained with Deep Learning models (which have reviewed millions of labeled NIR & PPG data points) in order to determine the correct level of each biomarker. Finally, the results are displayed through user-friendly wellness and prevention applications that can also share personalized recommendations to increase overall wellness.
Our Ambition
We wish to have assisted in lowering the proliferation of Type II Diabetes by promoting regular wellness monitoring with Bioviit. We also envision integrating additional biomarkers such as Cholesterol, Triglycerides, Insulin and Oxidative Stress, which would significantly expand our value proposition, promote form factor iteration, and maybe even represent an opportunity to license our processing technology to other Consumer Healthcare and Medtech companies that hold a larger customer base. The non-invasive wellness monitoring space (particularly glucose measurement) is of interest to large corporations, which is why we believe that we could be acquired before the 5 year mark.